Novartis's Gilenya gets EU and US label changes
This article was originally published in Scrip
Executive Summary
Novartis' Gilenya (fingolimod), the first ever multiple sclerosis pill, will have its label updated in both the EU and US to better manage potential adverse effects on the heart.